Cite
HARVARD Citation
Jørgensen, K. et al. (2017). Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 389 (10086), pp. 2304-2316. [Online].